We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

73 hedge funds and large institutions have $102M invested in Tvardi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,253% more call options, than puts

Call options by funds: $1.72M | Put options by funds: $73K

283% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 6

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

128% more capital invested

Capital invested by funds: $44.9M → $102M (+$57.3M)

30% more funds holding

Funds holding: 56 → 73 (+17)

7.23% more ownership

Funds ownership: 20.78% → 28% (+7.2%)

Holders
73
Holders Change
+17
Holders Change %
+30.36%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
23
Reduced
6
Closed
6
Calls
$1.72M
Puts
$73K
Net Calls
+$1.65M
Net Calls Change
+$1.65M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$4.75M
2
Invesco
Invesco
Georgia
+$2.35M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.34M
4
PHP
Parkman Healthcare Partners
Connecticut
+$1.85M
5
BlackRock
BlackRock
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$583K
2
HT
Headlands Technologies
Illinois
-$80K
3
Bank of America
Bank of America
North Carolina
-$49.1K
4
Morgan Stanley
Morgan Stanley
New York
-$31.5K
5
Citigroup
Citigroup
New York
-$30.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$27.4M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$16.3M +$591K +20,757 +5%
BlackRock
3
BlackRock
New York
$12.9M +$1.77M +62,039 +23%
6CM
4
683 Capital Management
New York
$6.77M – – –
VPC
5
Vestal Point Capital
New York
$6.51M +$4.75M +167,000 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$5.77M +$1.02M +35,781 +32%
Invesco
7
Invesco
Georgia
$3.22M +$2.35M +82,614 New
Fidelity Investments
8
Fidelity Investments
Massachusetts
$3.2M +$2.34M +82,216 +1,644,320%
PHP
9
Parkman Healthcare Partners
Connecticut
$2.53M +$1.85M +65,000 New
State Street
10
State Street
Massachusetts
$2.45M +$607K +21,335 +51%
UBS Group
11
UBS Group
Switzerland
$1.89M +$545K +19,126 +65%
FCM
12
Farallon Capital Management
California
$1.68M – – –
Northern Trust
13
Northern Trust
Illinois
$1.65M +$341K +11,975 +39%
Renaissance Technologies
14
Renaissance Technologies
New York
$1.18M -$30.2K -1,059 -3%
Goldman Sachs
15
Goldman Sachs
New York
$936K +$684K +24,029 New
SAM
16
Silvercrest Asset Management
New York
$872K +$637K +22,366 New
DWAM
17
Duncan Williams Asset Management
Tennessee
$859K +$5.69K +200 +0.9%
BFM
18
Boothbay Fund Management
New York
$787K +$575K +20,189 New
SSA
19
Schonfeld Strategic Advisors
New York
$746K +$545K +19,132 New
Bank of America
20
Bank of America
North Carolina
$599K -$49.1K -1,723 -10%
Charles Schwab
21
Charles Schwab
California
$595K +$91.7K +3,222 +27%
MAM
22
Monaco Asset Management
Monaco
$530K +$387K +13,590 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$377K +$275K +9,666 New
Squarepoint
24
Squarepoint
New York
$318K +$232K +8,164 New
Barclays
25
Barclays
United Kingdom
$260K +$25.1K +880 +15%
1
2 3 4

TVRD Hedge Fund Activity: Q3 2025 in Review

73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2025, worth a combined $102M — up 128% from $44.9M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TVRD positions and 6 closed out — a net gain of 17 holders — while 23 added to existing stakes and 6 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $4.75M. The largest seller was Marshall Wace, exiting entirely with an estimated $583K sold.

  • 73 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2025, up from 56 in Q2 2025.
  • Funds reported $102M of Tvardi Therapeutics stock for Q3 2025, up 128% quarter-over-quarter.
  • 23 funds opened new Tvardi Therapeutics positions in Q3 2025 and 6 closed out, a net change of +17 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $4.75M added.
  • The largest Tvardi Therapeutics seller in Q3 2025 was Marshall Wace, an estimated $583K sold.

Based on aggregated 13F filings for Q3 2025.